Phase III long-term safety study of SJP-0135 in patients with primary open-angle glaucoma or ocular hypertension - A long-term safety study of SJP-0135 in patients with primary open-angle glaucoma or ocular hypertension

Senju Pharmaceutical co.,ltd.0 个研究点目标入组 125 人开始时间: 2017年3月9日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) History of surgical intervention or laser treatment for glaucoma 2) History of intraocular surgery 3) Presence of any circulatory failure such as cerebrovascular disease, orthostatic hypotension, cardiovascular disease and not eligible in the opinion of the investigator or the sub-investigator 4) Presence or history of bronchial asthma, bronchospasm or serious chronic obstructive pulmonary disease 5) Presence or history of uncontrolled heart failure, sinus bradycardia, atrioventricular block (Grade II or III) or cardiogenic shock 6) Presence of right heart failure caused by pulmonary hypertension, congestive heart failure, diabetic ketoacidosis, metabolic acidosis or uncontrolled diabetes mellitus 7) Serious visual field defect 8) History of corneal transplantation or keratorefractive surgery

发起方